Literature DB >> 7988947

A prospective epidemiological study on the occurrence of antiphospholipid antibody: the Montpellier Antiphospholipid (MAP) Study.

J F Schved1, C Dupuy-Fons, C Biron, I Quére, C Janbon.   

Abstract

The objective of this study was to determine the prevalence and clinical significance of elevated antiphospholipid antibodies (APA) in a large series of patients admitted to a department of Internal Medicine. At the end of entry phase, 1014 patients were tested (488 males-526 females, mean age: 66.7 years, range 18-97). Seventy-two (7.1%) patients were found APA positive at least once: 44 males and 28 females, mean age 69 years, range 23 to 94. Twenty fulfilled the criteria of Primary Antiphospholipid Antibody Syndrome: 10 patients were referred for deep vein thrombosis, 3 had history of deep vein thrombosis, 1 had both arterial thrombosis and a history of venous thrombosis; 2 had thrombocytopenia; 3 had stroke, 1 had a history of a stroke. One patient had SLE according to ARA classification. The most frequent associated disease was cancer: 14 patients, 9 had evolutive malignant disease, 5 were in clinical remission of neoplasia. Other clinical conditions included chronic and/or acute alcoholic intoxication (n = 8), severe atherosclerosis (n = 4), leg ulcer (n = 4). Insufficient data are available about the evolution, but 7 patients died in the year following diagnosis. Eight patients had fluctuations in APA detection: 2 initially APA positive became negative, 5 initially negative became positive and 1 patient was alternatively positive, negative and positive without steroid treatment. Thus, as expected, APA occur in a variety of clinical disorders. The association with cancer or alcoholic intoxication deserves further investigations.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7988947     DOI: 10.1159/000217099

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  13 in total

Review 1.  Diagnosis and management of inherited and acquired thrombophilias.

Authors:  F A Spencer; R C Becker
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

Review 2.  Association of anticardiolipin antibodies with vascular injury: possible mechanisms.

Authors:  Y S Haviv
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

3.  High titres of IgM-antiphospholipid antibodies are unrelated to pathogenicity in patients with non-Hodgkin's lymphoma.

Authors:  W Miesbach; I Scharrer; R A Asherson
Journal:  Clin Rheumatol       Date:  2006-05-24       Impact factor: 2.980

4.  Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies.

Authors:  Wolfgang Miesbach; Inge Scharrer; Ronald Asherson
Journal:  Clin Rheumatol       Date:  2006-01-25       Impact factor: 2.980

5.  Aspirin thromboprophylaxis of asymptomatic antiphospholipid-positive subjects.

Authors:  Monica Galli
Journal:  Intern Emerg Med       Date:  2008-11-21       Impact factor: 3.397

Review 6.  The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis.

Authors:  Ewa Olech; Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

Review 7.  Epidemiology, Pathophysiology, and Natural History of Pulmonary Embolism.

Authors:  Meredith Turetz; Andrew T Sideris; Oren A Friedman; Nidhi Triphathi; James M Horowitz
Journal:  Semin Intervent Radiol       Date:  2018-06-04       Impact factor: 1.513

Review 8.  Malignancies and catastrophic anti-phospholipid syndrome.

Authors:  Wolfgang Miesbach
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 9.  Antiphospholipid syndrome and cancer.

Authors:  Eyal Reinstein; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

10.  The role of malignancies in patients with catastrophic anti-phospholipid (Asherson's) syndrome.

Authors:  W Miesbach; R A Asherson; R Cervera; Y Shoenfeld; J Gomez Puerta; G Espinosa; S Bucciarelli
Journal:  Clin Rheumatol       Date:  2007-05-24       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.